Lessee, Operating Lease, Liability, Undiscounted Excess Amount of Intra-Cellular Therapies, Inc. from 31 Mar 2019 to 31 Dec 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.
Summary
Intra-Cellular Therapies, Inc. quarterly Lessee, Operating Lease, Liability, Undiscounted Excess Amount in USD history and change rate from 31 Mar 2019 to 31 Dec 2024.
  • Intra-Cellular Therapies, Inc. Lessee, Operating Lease, Liability, Undiscounted Excess Amount for the quarter ending 31 Dec 2024 was $3,704,000, a 21% decline year-over-year.
Source SEC data
View on sec.gov
Lessee, Operating Lease, Liability, Undiscounted Excess Amount, Quarterly (USD)
Lessee, Operating Lease, Liability, Undiscounted Excess Amount, YoY Quarterly Change (%)

Intra-Cellular Therapies, Inc. Quarterly Lessee, Operating Lease, Liability, Undiscounted Excess Amount (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $3,704,000 -$968,000 -21% 31 Dec 2024 10-K 21 Feb 2025 2024 FY
Q3 2024 $4,089,000 -$976,000 -19% 30 Sep 2024 10-Q 30 Oct 2024 2024 Q3
Q2 2024 $4,457,000 -$1,011,000 -18% 30 Jun 2024 10-Q 07 Aug 2024 2024 Q2
Q1 2024 $4,292,000 -$1,592,000 -27% 31 Mar 2024 10-Q 07 May 2024 2024 Q1
Q4 2023 $4,672,000 -$1,638,000 -26% 31 Dec 2023 10-K 22 Feb 2024 2023 FY
Q3 2023 $5,065,000 30 Sep 2023 10-Q 02 Nov 2023 2023 Q3
Q2 2023 $5,468,000 30 Jun 2023 10-Q 03 Aug 2023 2023 Q2
Q1 2023 $5,884,000 31 Mar 2023 10-Q 04 May 2023 2023 Q1
Q4 2022 $6,310,000 31 Dec 2022 10-K 01 Mar 2023 2022 FY
Q4 2019 $12,011,945 31 Dec 2019 10-K 02 Mar 2020 2019 FY
Q3 2019 $12,541,905 30 Sep 2019 10-Q 05 Nov 2019 2019 Q3
Q2 2019 $13,078,145 30 Jun 2019 10-Q 07 Aug 2019 2019 Q2
Q1 2019 $13,617,662 31 Mar 2019 10-Q 08 May 2019 2019 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.